Press "Enter" to skip to content

Aurobindo Pharma gets 10 observations from USFDA for its Unit 3 at Hyderabad

The United States Food and Drug Administration (USFDA) conducted an inspection at company’s Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad, from May 13 to May 24, 2019, Aurobindo Pharma said in a filing to the BSE.

Original source: https://health.economictimes.indiatimes.com/news/pharma/aurobindo-pharma-gets-10-observations-from-usfda-for-its-unit-3-at-hyderabad/69658453?utm_source=RSS&utm_medium=ETRSS